
    
      Background:

        -  Study subjects exposed to gene therapy interventions may be at risk for delayed or long
           term adverse consequences. The U.S. Food and Drug Administration (FDA) has issued Draft
           Guidance for Industry: Long Term Follow-up After Administration of Human Gene Therapy
           Products, which outlines a framework to assess the risk of gene therapy-related delayed
           adverse events and the essential elements appropriate for the conduct of long-term
           follow up observations.

        -  Accordingly some vector designs (i.e. use of an adenovirus), based on duration of
           persistence accompanied by cumulative preclinical and clinical evidence, may require
           shorter periods of observation than other vector designs (i.e. use of a lentivirus).

      Objectives:

      - To conduct long term safety evaluations after administration of genetically engineered
      cellular therapy to subjects who have participated in POB clinical trials.

      Eligibility:

      -Subjects who have received at least one dose of a genetically engineered cellular therapy on
      a POB gene therapy clinical trial are eligible to participate.

      Design:

        -  Subjects will be evaluated for long term safety and occurrence of adverse events
           according to the requirements established by the POB gene therapy parent protocol, the
           FDA guidance and the NIH Guidelines for Research Involving Recombinant or Synthetic
           Nucleic Acid Molecules (NIH Guidelines), to include:

        -  Long term follow up after genetically engineered cellular therapy:

             -  Post-cell infusion evaluations for T-Cell persistence (if applicable)

             -  Monitoring for replication-competent retrovirus (RCR) or replication-competent
                lentivirus (RCL)

             -  For 5 years: Physical examination

             -  For 10 additional years: Complete Questionnaire

        -  To ensure adequate follow up for patients in POB receiving genetically engineered
           cellular therapy, a maximum accrual of 500 patients will be allowed on this study. To
           accommodate 15-year follow-up of all patients, this study will remain open until 2050
    
  